News

Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Why Novo Nordisk Stock Slipped Today
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Devdiscourse14h
Novo Nordisk Faces Challenges as Copycat Competition Intensifies
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
Health Care Down on Novo Nordisk Earnings -- Health Care Roundup
Health-care companies fell as investors continued to retreat from formerly hot areas such as obesity-drug and vaccine makers. Shares of Novo Nordisk continued their slide despite reporting a ...
Novo Nordisk to advance ATTR amyloidosis mAb to Phase III
Novo Nordisk will advance its acquired ATTR amyloidosis with cardiomyopathy monoclonal antibody (mAb) to Phase III trials.